Affordable Access

Histology-driven chemotherapy of soft-tissue sarcoma.

Publication Date
  • Medicine And Health Sciences
  • Biology
  • Medicine


Soft-tissue sarcomas are rare diseases with >50 subtypes. Surgery is the most important treatment in localized disease, sometimes combined with radiotherapy. Chemotherapy is used as palliation in advanced disease, sometimes also with a potential to decrease tumour size and eradicate micro-metastases, making meaningful surgery possible. The role of chemotherapy as adjuvant treatment in localized disease is not finally settled. Doxorubicin and ifosfamide are the two drugs with the best established response rates in soft-tissue sarcoma, and a combination of these drugs has been a 'gold standard' for several years. However, there is an emerging knowledge of the biology and sensitivity to treatment for different histological subtypes. New drugs such as gemcitabine, taxanes and trabectedin have been explored in several studies, showing promising results. Even if most studies have encompassed many different subtypes and were limited in size, knowledge related to specific treatment for different subtypes is emerging. Examples are trabectedin in liposacoma and leiomyosarcoma, and taxanes in angiosarcoma.

There are no comments yet on this publication. Be the first to share your thoughts.


Seen <100 times

More articles like this

Histology-driven chemotherapy in soft tissue sarco...

on Current treatment options in o... March 2011

Histology- and non-histology-driven therapy for tr...

on Annals of Oncology September 2012

Histology and imaging of soft tissue sarcomas

on European Journal of Radiology Jan 01, 2009
More articles like this..